News

Showing posts for — Year: 2017

02.21.17

VALEANT PHARMACEUTICALS AND EYEGATE ENTER INTO LICENSING AGREEMENT FOR EGP-437 COMBINATION PRODUCT IN POST-OPERATIVE PAIN AND INFLAMMATION IN OCULAR SURGERY PATIENTS

Novel Approach Offers Eye Care Practitioners Delivery Alternative for Post-Operative Therapeutic Regimens LAVAL, QUEBEC and WALTHAM, MA – FEBRUARY 21, 2017 - Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX:...
02.06.17

EyeGate Pharmaceuticals Announces Executive Promotions

Sarah Romano named Interim Chief Financial Officer; Lisa Brandano and Carol Assang promoted to Vice President, Clinical Operations and Director, Clinical Operations, respectively WALTHAM, Mass., February 06, 2017 — EyeGate...
01.30.17

EyeGate Pharma Announces Positive Top-line Data from First-in-Human Pilot Trial of Ocular Bandage Gel in Corneal Epithelial Defects

Company Plans to Continue Development with Next Controlled Trial Q2 2017 WALTHAM, Mass., January 30, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company...
01.24.17

EyeGate Pharmaceuticals to Present at the Noble Financial Capital Markets’ 13th Annual Investor Conference

WALTHAM, Mass., January 24, 2017 — EyeGate Pharmaceuticals, Inc. (NASDAQ:EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing therapeutics and drug delivery systems for...
01.23.17

EyeGate Pharma Awarded Canadian Patent for Proprietary Iontophoretic Formulation and Use of the Formulation for Ocular Delivery of Dexamethasone Phosphate

Patent Further Strengthens EyeGate’s Global IP Protection for Lead Product Candidate, EGP-437 WALTHAM, Mass., January 23, 2017 -- Eyegate Pharmaceuticals, Inc. (NASDAQ: EYEG) ("EyeGate" or the "Company"), a specialty pharmaceutical...
01.09.17

EyeGate Receives Additional Milestone Payment from Valeant Pharmaceuticals for EGP-437

WALTHAM, Mass., Jan. 09, 2017 -- EyeGate Pharmaceuticals, Inc. (NASDAQ: EYEG) (“EyeGate” or the “Company”), a specialty pharmaceutical company that focuses on developing and commercializing products for treating diseases and...